ctDNA Predicts Overall Survival in Patients With NSCLC Treated With PD-L1 Blockade or With Chemotherapy.
Wei ZouStephanie J YaungFrederike FuhlbrückMarcus BallingerEric PetersJohn F PalmaDavid S ShamesDavid R GandaraYuqiu JiangNamrata S PatilPublished in: JCO precision oncology (2022)
ctDNA MMPM levels measured at 6 weeks post-treatment are associated with OS in advanced non-small-cell lung cancer. Our results suggest that ctDNA has the potential for a noninvasive early liquid biopsy predictor for OS that warrants further studies to demonstrate its utility in clinical development.
Keyphrases
- advanced non small cell lung cancer
- circulating tumor
- epidermal growth factor receptor
- small cell lung cancer
- ionic liquid
- ultrasound guided
- tyrosine kinase
- locally advanced
- circulating tumor cells
- radiation therapy
- fine needle aspiration
- combination therapy
- case control
- risk assessment
- gestational age
- newly diagnosed
- replacement therapy